By leveraging patent thickets aimed at extending the market monopolies on their blockbuster drugs, these companies seek to maximize revenue streams while delaying the entry of low-cost generic alternatives
You have a triple agonist with the strongest single-compound weight-loss record in modern obesity research, plus an amylin analog with a standalone double-digit result and a phase 3 combination precedent proving amylin adds to GLP-1
Similarly, this latter analysis, which covered nearly 2.25 million patients, did not show an excess risk of suicidal ideation and behavior in patients taking GLP-1s
The possibility that GLP-1 receptor agonists may be effective for some substance use disorders is promising, but we need large randomized controlled trials to confirm benefit and clarify for whom they work best, he says
The Trial The ATTAIN-MAINTAIN trial enrolled patients who had achieved substantial weight loss that had plateaued while taking weekly injectable GLP-1s in the SURMOUNT-5 trial
If more than 5 days have passed, skip the missed dose and resume at your next scheduled day
